For your adult patients with
MDS-associated anemia*

With Reblozyl®▼ —the first and only erythroid maturation agent
—you can reduce or even eliminate patients’ red blood cell
(RBC) transfusion dependence.1-3

Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the treatment of adult

  • with transfusion-dependent anemia due to very low, low or intermediate-risk (IPSS-R)
    myelodysplastic syndrome (MDS) with ring sideroblasts, who had an unsatisfactory
    response to or are ineligible to erythropoietin-based therapy
  • with transfusion-dependent anemia associated with β-thalassemia.

The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25mg/kg
every 21 days for beta-thalassemia.

Reblozyl®▼ treatment will stop being reimbursed if:

  • there is no reduction of the transfusion burden after 9 weeks (3 cycles) at the
    maximum dose level, if the lack of response cannot be explained otherwise
    (bleeding, surgical intervention, other concomitant disease) or,
  • anytime in case of unacceptable toxicities. 4

▼This medicinal product is subject to additional monitoring. This will allow quick
Identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. Before prescribing Reblozyl®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.